



200.1133CON5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.: 10/700,906
Applicant: Benjamin OSHLACK et al.
Filed: November 4, 2003
Art Unit: 1615
Examiner: Humera N. SHEIKH
For: **TAMPER-RESISTANT ORAL OPIOID
AGONIST FORMULATIONS**

Mail Stop: AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

June 15, 2009

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with Applicants' duty of disclosure under 37 C.F.R. § 1.56 and the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants submit herewith copies of:

- (i) the Office Action issued on August 11, 2005, in U.S. Serial No. 10/214,408;
- (ii) the Office Action issued on October 2, 2007, in U.S. Serial No. 11/352,900; and
- (iii) the Office Action issued on November 28, 2008, in U.S. Serial No. 11/352,900.

It is respectfully requested that the information in the Office Actions be considered in its entirety and made of record.


This Information Disclosure Statement is filed under 37 C.F.R. § 1.97(c), "before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application" and is accompanied by a check to

cover the fee set forth in § 1.17(p). In the event any additional fee is due or an overpayment has been made in connection with the filing of this Information Disclosure Statement, the Commissioner is hereby authorized to charge said fee or credit said overpayment to our Deposit Account No. 50-0552.

Respectfully submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

By:


Oleg Ioselevich
Reg. No. 56,963

DAVIDSON, DAVIDSON & KAPPEL, LLC
Patents, Trademarks and Copyrights
485 Seventh Avenue, 14th Floor
New York, New York 10018
(212) 736-1940